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Abbreviations: 
DTT, dithiothreitol  
hyLYS, lysozyme multimers with significant intermolecular disulfides and hyper 
molecular mass 
IPTG, isopropylthiogalactoside 
2-ME, 2-mercaptoethanol 
M. lyso, Micrococcus lysodeikticus 
mPDI-P5, mature protein disulfide isomerase-P5 
NEM, N-ethylmaleimide 
NR, non-reducing conditions 
PBS, phosphate-buffered saline 
Protein disulfide isomerase-P5, PDI-P5 or P5 
R, reducing conditions 
T-TBS, TBS containing 0.05% Tween 20 
1 
 
ABSTRACT 
Protein disulfide isomerase-P5 (P5) is thought to have important functions as an 
oxidoreductase, however, molecular functions of P5 have not been fully elucidated. P5 has 
been reported to have insulin reductase activity and inhibit lysozyme refolding by formation 
of lysozyme multimers with hyper molecular mass inactivated by intermolecular disulfides 
(hyLYS) in oxidative refolding of reduced denatured lysozyme. To explore the role of each 
domain of P5, I investigated the effects of domain deletion and Cys-Ala mutants of P5 on 
insulin reduction and the oxidative refolding of the lysozyme. The mutants of catalytic 
cysteines, C36/39A, C171/174A, and C36/39/171/174A inhibited the lysozyme refolding 
almost similarly to P5, and even b domain without catalytic cysteines showed moderate 
inhibitory effect, suggesting that the b domain played a key role in the inhibition. Western 
blotting analysis of the refolding products indicated that the catalytic cysteines in both the a 
and a’ domains cross-linked lysozyme comparably to form hyLYS resistant to trypsin, in 
which b domain was suggested to capture lysozyme for the significant sulfhydryl oxidation. 
The mutant of the conserved cysteines in b domain, C272/278A, did not form hyLYS, 
however, showed predominant reductase activity, implying that P5 functioned as a potent 
sulfhydryl oxidase and a predominant reductase depending on the circumstance around 
C272/278. These results provide new insight into the molecular basis of P5 function. 
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INTRODUCTION 
 
Protein disulfide isomerase (PDI) family, which typically has CXXC active sites, 
catalyzes the formation, isomerization, and reduction of disulfide bonds of proteins (App. 1 
and 2) [1, 2]. PDI plays the centering role for protein folding [3-5], and it is likely that each 
member plays a distinct role in protein maturation as an oxidoreductase [6]. Recently, Araki et 
al. have reported a hierarchical electron transfer network centering on the PDI-Ero1α complex, 
including ERp57, ERp46, and PDI-P5 (P5, ERp5 or PDIA6), suggesting a cooperative quality 
control network in the redox pathway (App. 3) [7].  
P5 has also been reported to be involved in asymmetric organogenesis in zebrafish [8], 
regulation of human platelet function [9], and regulation of Ca
2+
 signaling in mice and 
Caenorhabditis elegans [10, 11], human breast cancer invasion and metastasis [12], human 
tumor immune evasion triggered by disulfide reduction of the membrane-anchored ligand 
MICA by P5 [13]. In plants, GmPDIM (a soybean orthologue of human P5) has been reported 
to be involved in the folding of storage proteins [14]. PDIL2;3 (a rice orthologue of human 
P5) has been shown to have a function to retain GFP-AB (a protein body I-marker), the 
N-terminal region of α-globulin fused to GFP, within the endoplasmic reticulum (ER) by 
accumulating it via intermolecular disulfide cross-linkages, and promote sorting of the 
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cross-linked α-globulin to protein body I in vivo (App. 5) [15, 16]. Boar P5 has been reported 
to catalyze formation of lysozyme multimers with intermolecular disulfide bonds and hyper 
molecular mass (hyLYS) in oxidative refolding of reduced denatured lysozyme (App 6) [17]. 
This property of boar P5 is similar to that of rice P5 to introduce intermolecular disulfides into 
reduced denatured -globulins (C79F) to form α-globulin multimers with hyper molecular 
mass in vitro [15].  
Considering that P5 is localized not only in the ER but also in mitochondria [18], and 
membrane surface [13], P5 is thought to have important functions as an oxidoreductase. 
However, molecular functions of P5 have not been fully understood yet. Kikuchi et al. has 
reported that a domain of human P5 is more important for isomerase activity than a’ domain 
using Cys-Ser mutants [19]. However, years later, Tian et al. have mentioned that Cys-Ser 
mutants of PDI have reducing activity in scrambled RNase A refolding due to its hydroxyl 
group [20]. In addition, several protein disulfide isomerases such as ERp44 with an active-site 
sequence, CRFS [21], and PDILT with those, SKQS and SKKC [22], have been identified. 
These imply that there is a possibility of different interpretation of the study using Cys-Ser 
mutants [19]. 
In the present study, I investigated the effects of domain-deletion and Cys-Ala variants of 
P5 on insulin reductase activity, and the oxidative refolding of the lysozyme followed by 
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Western blotting analysis of the refolding products, to elucidate the role of each domain of P5 
and its molecular function. This study demonstrated that P5 formed hyLYS resistant to trypsin, 
in which the redox-active cysteines in both the a and a’ domains participated almost 
comparably. And also, the conserved C272/278 in the b domain were suggested to play a key 
role to capture the substrate lysozyme in the formation of hyLYS, and implied a possible 
activity shift of P5 from a potent sulfhydryl oxidase to a predominant reductase vice versa 
dependent on the circumstance around C272/278. 
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MATERIALS AND METHODS 
 
1. Plasmid construction for expression of full-length P5 and its variants 
 
DNA fragments encoding the a, aa', a'b, or b domains of boar mature P5 were amplified 
by PCR using the plasmid pET-mPDI-P5 [17] as a template and subcloned into the Bam HI 
and Hind III sites of the expression vector pET30a(+) (Novagen). The mutations C36/39A, 
C171/174A, and C36/39/171/174A were introduced by direct mutagenesis using Cys-Ala 
single mutants as templates, which were produced by direct mutagenesis by PCR with 
complementary mutagenic primers (Table 1). After PCR, the template DNA was digested with 
Dpn I [23], followed by transformation and plasmid preparation. The double mutation of 
C272/278A with complementary mutagenic primers (Table 1) was not successfully introduced 
into pET-P5, thereby, an alternative plasmid, pUC-mPDI-P5 was constructed and used as a 
template. The DNA fragment encoding C272/278A in pUC118 was subsequently inserted into 
the BamHI and HindIII sites of the expression plasmid, pET30a(+). The pUC118 was kindly 
provided by Professor Miyakawa at Yamanashi University. The nucleotide sequences of the 
domain and Cys-Ala-substitution variants in pET30a(+) were confirmed by sequencing using 
the dye terminator method on a 3130x1 genetic analyzer (Applied Biosystems).  
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2. Expression and purification of P5 and its derivatives  
 
The expression vectors were transformed into competent HMS174 (DE3) Escherichia 
coli (E. coli.). Cells harboring the plasmids were grown at 37°C until the OD600 reached 0.8 – 
1.0. Expression was induced by addition of IPTG to a final concentration of 0.4 mM, and the 
cells were harvested after 3 hr of incubation at 37°C by centrifugation (12000 × g, 10 min, 
4°C). 
I combined ammonium sulfate precipitation and three types of chromatography to highly 
purify P5 and its variants, as described in Table 2. Briefly, the cells from 50 mL of culture 
were sonicated on ice, followed by centrifugation (12000 × g, 10 min, 4°C). Supernatant was 
subjected to ammonium sulfate precipitation (80% saturation; Table 2) for 1 hr on ice. The 
precipitate was resolubilized and applied to a phenyl-Sepharose CL-4B column (GE 
Healthcare Bio-Sciences). Proteins including P5 were eluted with Tris-AcOH basal buffer 
containing 1% Triton-X 100 (pH 6.5), then loaded onto a column of Chelating Sepharose Fast 
Flow (GE Healthcare Bio-Sciences). His-tagged P5 was eluted with phosphate basal buffer 
containing 500 mM imidazole (pH 7.8). After buffer-exchange with 20 mM Tris-HCl (pH 7.0) 
by ultrafiltration (4000 × g, 10 min, at 4°C) (Amicon-Ultra-4 centrifugal filter unit, Millipore), 
the N-terminal His-tag was digested with recombinant enterokinase (Novagen) for 16 hr at 
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20°C. For further purification, (Ala-Met-Ala-Asp-Ile-Gly)-P5 was applied to a column of 
DEAE-Sephacel (Sigma). P5 was eluted with Tris-HCl buffer containing 300 mM NaCl (pH 
7.0), and buffer-exchanged with PBS (pH 7.4) by ultrafiltration as described above. 
Purification of Cys-Ala mutants except for C272/278A was performed in the same manner as 
described above. The a, aa', a'b, and b domains and C272/278A were also purified in a similar 
manner as full-length P5 with a slight modification (Table 2). 
 
3. Insulin turbidity assay 
 
Insulin turbidity assay was carried out essentially according to Holmgren’s method [24] 
with a slight modification [25]. Insulin solution in the presence or absence of P5 or Cys-Ala 
mutants or a'b was preincubated in a sample cuvette for 10 min at 25°C. The reactions 
catalyzed by P5 or the variants were initiated by addition of DTT, giving a final concentration 
of 1.0 mM insulin/100 mM sodium phosphate/1.0 mM EDTA·2Na/1.0 mM DTT (pH 7.0) in 
the presence of P5 or the variants. The absorbance at 540 nm at 25°C was monitored for 2200 
s. Measurements were performed in duplicate with a dual wavelength spectrophotometer 
(U-2001, Hitachi). 
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4. Oxidative refolding assay of reduced denatured lysozyme  
 
Lysozyme refolding assay was performed essentially according to the method of Puig 
and Gilbert [26, 27] as described previously [17] (Fig. 1). Lysozyme was reduced and 
denatured by incubation in denaturation buffer (8 M urea/130 mM 2-mercaptoethanol/25 mM 
Tris-HCl, pH 8.6) for 90 min at 37°C. Denaturation was quenched by 10-fold dilution with 
0.1 M acetic acid, pH 4.0. The denatured lysozyme was refolded in refolding buffer for 60 
min at 37°C, giving its final composition of 1.4 µM lysozyme/100 mM HEPES/20 mM 
NaCl/2 mM EDTA/5 mM MgCl2/5 mM GSH/0.5 mM GSSG, pH 7.0. All refolding 
experiments were performed in a volume of 200 μL in siliconized polypropylene tubes to 
minimize protein adsorption [17, 26]. Aliquots of 30 µL of the lysozyme refolding solution 
were sampled every 20 min and added to the Micrococcus lysodeikticus cell wall suspension 
(0.5 mg/mL of 50 mM sodium phosphate, pH 6.2) to initiate bacteriolysis, accompanying the 
decrease in absorbance at 540 nm. Measurements were performed in triplicate in the presence 
or absence of P5 or its variants using a dual wavelength spectrophotometer (U-2001, Hitachi) 
for 304 sec at 25°C. Lysozyme activity was derived from the slope of the decrease in 
absorbance against that of native lysozyme. 
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5. Western blotting analysis 
 
    Lysozyme refolding products, after incubation for 0 – 60 min in the presence or absence 
of P5 or its variants, were boiled in 2% SDS-PAGE sample buffer containing 3 mM 2-ME or 
5 mM N-ethylmaleimide (NEM) and separated in a Tris-Tricine buffer system on 7.5% 
polyacrylamide gels [28]. Proteins in the gel were transferred onto PVDF membranes 
(Millipore) and analyzed by Western blotting with antibodies against both lysozyme and P5. 
The following primary antibodies were used: anti-lysozyme rabbit polyclonal antibody 
(α-LYS) (ab34799; Abcam) (diluted 1:10000 with 3% ECL blocking agent/T-TBS); 
anti-human PDI-P5 rabbit polyclonal antibody (α-P5), raised against amino acids 192-440 of 
human P5 (ERp5 (H-249): sc-292227; Santa Cruz Biotechnology) (diluted 1:500 with 3% 
ECL blocking agent/T-TBS). After washing three times with T-TBS, the membranes were 
incubated with goat anti-rabbit horseradish peroxidase-conjugated immunoglobulin G (IgG) 
antibody (Sigma) solution (diluted 1:5000 with 3% ECL blocking agent/T-TBS), followed by 
ECL Western blotting detection system (GE Healthcare Biosciences). 
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6. Trypsin sensitivity of refolding lysozyme in the presence or absence of P5 and 
C36/39/171/174A 
 
For the negative control, 1.4 µM of lysozyme was prepared by dissolving with 50 mM 
sodium phosphate, pH 6.2, to be the sample of native lysozyme. Recued denatured lysozyme 
was prepared and quenched in the same manner as described in MATERIALS AND 
METHODS 4. The quenched lysozyme was used as a sample of reduced denatured lysozyme, 
while the lysozyme refolded for 60min in the presence or absence of P5 and 
C36/39/171/174A was used as a sample of refolding lysozyme. The native lysozyme and 
reduced denatured lysozyme were treated with trypsin (V511A; Promega, Madison, WI) at 
enzyme/substrate weight ratio of 1:25 for 60 min at 37°C. The refolding lysozyme in the 
presence or absence of P5 or C36/39/171/174A was treated with trypsin for 30min under the 
same condition. The digested products were boiled in an equal volume of 2% SDS-PAGE 
sample buffer containing 5 mM NEM and subjected to Western blotting analysis as described 
in MATERIALS AND METHODS 5.  
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RESULTS AND DISCUSSION 
 
1. Purification of P5 and its mutants 
 
To investigate the mechanism by which P5 inhibits oxidative refolding of lysozyme, we 
constructed plasmids carrying the DNA fragments of the a, aa', a'b, and b domains and 
Cys-Ala mutants (Fig. 2). The pET E. coli expression system was utilized to generate P5 
variants. The expression of the resultant N-terminal His-tagged and 
(Ala-Met-Ala-Asp-Ile-Gly)-added proteins was induced with IPTG. I highly purified P5 and 
its variants by a combination of ammonium sulfate precipitation and three types of 
chromatography as shown in Fig. 3. 
 
2. Reducing activities of P5 variants 
 
P5 has been shown to have thiol-dependent reductase activity, which catalyzes the 
reduction of insulin disulfides by DTT [17]. I investigated the thiol-dependent reductase 
activities of P5 variants. The reductase activity of C171/174A was 12% relative to P5, 
showing the greatest decrease among C36/39A, C171/174A, and a’b (Fig. 4). These results 
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suggested that the a' domain had greater reductase activity than the a domain. 
C36/39/171/174A was catalytically impaired, indicating that the b domain had not insulin 
reductase activity (Fig. 4). 
 
3. Effects of domain deletion and Cys-Ala mutants of P5 on oxidative refolding of 
reduced denatured lysozyme 
 
It has been previously reported that ERp57 (PDIA3), the closest homolog of PDI, 
promotes oxidative refolding of reduced denatured lysozyme, while P5 inhibits oxidative 
refolding of the lysozyme in a dose-dependent manner at an equimolar ratio to lysozyme (Fig. 
5) by forming lysozyme multimers with hyper molecular mass inactivated by significant 
intermolecular disulfides (hyLYS) under the same conditions as ERp57 (App. 6) [17]. Then, I 
investigated the effects of domain deletion or Cys-Ala mutants on the oxidative refolding of 
the lysozyme to explore the essentials of the refolding inhibition. I used Cys-Ala mutants as 
Cys-substituted variants because serine has been reported to have residual reducing activity 
[20].  
In the absence of P5, the lysozyme activity was 38% after 60 min incubation in the 
refolding conditions used, while the activity in the presence of P5 was 2 %. The activities 
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after 60 min incubation in the presence of domain deletion and Cys-Ala mutants at 0.7 µM 
were summarized in Fig. 6. In the presence of C36/39A and C171/174A, the activities were 
8% and 12%, respectively (Figs. 6 and 7), suggesting that not only cysteines in the a domain 
but also those in the a’ domain participated comparably in the refolding inhibition. The 
inhibition in the presence of the double mutants showed dose-dependence (Figs. 8 and 9). 
C36/39/171/174A and b domain fragment, having none of catalytic cysteines, unexpectedly 
inhibited the refolding (Figs. 6 and 10-12), implying the importance of the b domain in the 
refolding inhibition. In contrast, aa’ domain fragment enhanced lysozyme refolding (Fig. 13). 
However, under the coincubation with aa’ domain and b domain, only the inhibitory effect of 
b domain was observed (Fig. 14). Similarly, a'b fragments inhibited the refolding (Fig. 15) 
even when a’b was coincubated with a domain (Fig. 16), which accelerated the refolding 
(data not shown). These observations suggested that b domain had a large impact on the 
refolding inhibition.  
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4. Western blotting analysis of refolding products 
 
In the previous study with Western blotting analysis of refolding products, P5 forms 
lysozyme multimers with significant intermolecular disulfides to be hyper molecular mass 
(hyLYS), which are not detected in the presence of ERp57 (App. 6-B) [17]. The hyLYS is too 
large to enter not only the gel for separating proteins but also the gel for concentrating them, 
and reduced to be monomeric form under the reducing conditions. However, Cys-Ala mutants 
did not show clear differences in the inhibition of lysozyme refolding, although 
C36/39/171/174A did not have catalytic cysteines. To interpret the results of the inhibition by 
the mutants with catalytic cysteines (C36/39A, C171/174A and a’b) and the mutants without 
catalytic cysteines (C36/39/171/174A and b), the refolding products in the presence of the 
variants were analyzed by Western blotting using anti-lysozyme antibody and anti-P5 
antibody, which did not cross react to each other (Fig. 17).  
In the absence of P5 and its variants, a portion of the denatured lysozyme formed 
intermediates with intermolecular disulfides (Fig. 18), which explained 38% of lysozyme 
activity after 60 min refolding. Lysozyme products after 60min refolding in the absence or 
presence of P5 and its variants were compared as shown in Fig.19. In the presence of P5, 
C36/39A and C171/174A, the lysozyme intermediates, detected when lysozyme alone, were 
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faded, while hyLYS were detected in the hyper molecular region (Fig. 19-A, lanes 1 vs 2-4). 
The difference between P5 and the double mutants became clearer with twice as much as the 
refolding products, showing the intermediates remained in the presence of the double mutants, 
while those did not in the presence of P5 (Fig. 20-A). In the presence of a’b, the amount of 
hyLYS were relatively less and the molecular mass of the lysozyme intermediates were 
smaller than that detected in the presence of C36/39A (Fig. 19-A, lanes 3 and 6 and Fig. 20-B). 
It was reasonable that both of the catalytic cysteines and the proper conformation of a domain 
were important for efficient formation of hyLYS, being in agreement with the result that 
C36/39A inhibited lysozyme refolding more greatly than a’b did (Fig. 6). The hyLYS were 
reduced to be a monomeric form under the reducing condition (Fig. 19-B). These observations 
evidenced that P5 catalyzed the formation of the hyLYS to inactivate lysozyme via significant 
intermolecular disulfide cross-linking, and demonstrated that the catalytic cysteines in both 
the a and a’ domains participated in the sulfhydryl oxidation almost comparably.  
C36/39/171/174A or b domain without catalytic cysteines unexpectedly inhibited the 
lysozyme refolding (Fig. 6). In the Western blotting, lysozyme intermediates indicated by the 
square bracket, which were similar to those in the presence of lysozyme alone (Fig. 18), were 
detected in the presence of C36/39/171/174A (Fig. 19-A, lane 5). These intermediates were 
detected in the presence of b domain as well (Fig. 19-A, lane 7). In addition, in the presence 
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of C36/39/171/174A, the amount of lysozyme multimers at the hyper molecular region was 
greater than those in the presence of P5 (Fig. 19-A, lanes 2 and 5). Because C36/39/171/174A 
did not have catalytic cysteines, the multimers in the presence of C36/39/171/174A were not 
the product due to the significant intermolecular cross-linking by catalytic cysteines. As 
shown by the results detected by anti-P5 antibody, the amount of C36/39/171/174A at the 
hyper molecular region was also greater than that of P5 (Fig. 19-A, lanes 9 and 12). These 
lysozyme multimers and C36/39/171/174A at the hyper molecular region detected by 
anti-lysozyme antibody and anti-P5 antibody, respectively, in the presence of 
C36/39/171/174A were independent of refolding buffer (Fig. 21) and SDS concentration (Fig. 
22, lanes 1-4), but reduced to be a monomeric form under the reducing condition (Fig. 22, 
lane 5). These data suggested a possible arrest of formation of hyLYS due to loss of catalytic 
cysteines to stay at the hyper molecular region as a mixed multimers via covalent bond(s). As 
shown in Fig. 23, most of a’b were in monomeric form (Fig. 23, lanes 1-4) throughout 60 min 
refolding, while the bands including b domain gradually migrated to the hyper molecular 
region (Fig.23, lanes 5-8), supporting the possible interaction of b domain with lysozyme to 
capture lysozyme in the formation of hyLYS. Considering that a’ domain showed a higher 
reductase activity toward insulin reduction than a domain (Fig. 4), a reason for less amount of 
a’b than b staying at the hyper molecular region was that a’ domain of a’b fragment might 
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reduce the mixed covalent bond(s) between lysozyme and a’b. 
 
5. Trypsin sensitivity of lysozyme multimers with hyper molecular mass formed by P5 
and C36/39/171/174A 
 
   P5 and C36/39/171/174A formed the lysozyme multimers at the hyper molecular region 
after 60 min refolding (Fig. 19-A, lanes 2 and 5). The lysozyme multimers in the presence of 
P5 progressed with time (Fig. 24, lanes 2-5), while those in the presence of C36/39/171/174A 
did not (Fig. 24, lanes 6-9), suggesting that these multimers were different in quality. To 
investigate whether P5 formed lysozyme multimers with the significant disulfide 
cross-linkages, while C36/39/171/174A formed a huge complex with lysozyme via b domain, 
I analyzed the sensitivities of the multimers formed in the presence of P5 and 
C36/39/171/174A toward trypsin. 
 Activity of native lysozyme was retained throughout trypsin treatment for 60 min (Fig. 
25) and correspondingly, the results of Western blotting showed that native lysozyme was not 
affected by trypsin (Fig. 25, lanes 1-5). When the reduced denatured lysozyme was treated 
with trypsin right after the addition of refolding buffer, lysozyme activity did not recover 
(1%) (Fig. 25), and the reduced denatured lysozyme was found to be digested by trypsin at 
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least for 30 min treatment (Fig. 25, lanes 6-10), indicating that native lysozyme with disulfide 
cross-linkages was relatively resistant to trypsin. 
 Activity of the lysozyme after 60 min refolding, followed by 30 min incubation with 
trypsin, slightly decreased from 38% to 29% (data not shown), and the lysozyme treated with 
trypsin for 30 min did not show notable change in Western blotting (Fig. 26, lanes 1 and 2 vs 
7 and 8), indicating that the regeneration of disulfides by refolding made the denatured 
lysozyme more resistant to trypsin (Fig. 26, lane 8 vs Fig. 25, lane 9). In the presence of P5 
and C36/39/171/174A, the lysozyme multimers with hyper molecular mass in the absence of 
trypsin increased slightly during additional refolding for 30min (Fig. 26, lanes 3-6), showing 
that formation of the multimers were progressed. With trypsin treatment for 30min after 
incubation for 60 min, the lysozyme multimers in the presence of P5 slightly decreased (Fig. 
26, lanes 3 and 4 vs 9 and 10), while the multimers in the presence of C36/39/171/174A 
notably decreased (Fig. 26, lanes 5 and 6 vs 11 and 12). These results indicated that P5 
formed hyLYS to be registrant to trypsin by the significant intermolecular disulfides, but 
C36/39/171/174A did not. 
PDIL2;3 (a rice orthologue of human P5) introduces intermolecular cross-linkages into 
reduced denatured α-globulin (C79F) in vitro [15], and retains GFP-AB within the ER by 
accumulating it via intermolecular disulfide cross-linkages, and promote sorting of the 
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cross-linked -globulin to protein body I in vivo (App. 5) [16]. Considering these findings 
together with the results of this study, P5 may function as a regulator to pack proteins to 
be ready for transport by intermolecular disulfide cross-linking.  
 
6. Effects of the mutations of absolutely conserved C272/278 on formation of the 
lysozyme multimers with intermolecular disulfides and hyper molecular mass and on 
insulin reduction 
 
The b domain was suggested to interact with refolding lysozyme via covalent bond(s) as 
described above (Figs. 19, 22 and 23). The cysteines (C272 and C278) in the b domain are 
absolutely conserved among animals and plants (Fig. 27), thereby, I speculated that the 
cysteines could be the key for the formation of hyLYS. To further investigate a role of b 
domain, I examined effects of C272/278A on lysozyme refolding and insulin reduction. The 
refolding activity in the presence of C272/278A was 16±3% (Fig. 28-A). In Western blotting 
analysis, neither of hyLYS nor C272/278A at the hyper molecular region were detected by 
anti-lysozyme antibody and anti-P5 antibody, respectively in the presence of C272/278A 
having the catalytic cysteines (Fig. 28-B, lanes 4-7), while in the presence of P5 and 
C36/39/171/17A, having C272/278, hyLYS, and P5 and C36/39/171/17A in the hyper 
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molecular regions were detected by anti-lysozyme antibody and anti-P5 antibody, 
respectively (Fig. 28-B, lanes 2 and 3). These results indicated the C272 and/or C278 played a 
key role to capture lysozyme in forming hyLYS. Prediction of secondary structures using 
bioinformatics tool, SOPMA, showed that the mutations of C272/278 to C272/278A caused 
conformational changes of extended strands and beta turns around C272/278 to alpha helixes. 
C272 and/or C278 was/were thought to be necessary to maintain the conformation to provide 
P5 a platform to form hyLYS, although possible covalent interactions with lysozyme via 
C272/278 for formation of hyLYS was also considered as described above (Figs. 19, 22 and 
23). 
Furthermore, C272/278A showed predominant reductase activity toward insulin (Fig. 
28-C), suggesting a possibility that P5 functions as a potent sulfhydryl oxidase and a 
predominant reductase, depending on the circumstance around C272/278.  
 
7. Significance of b domain with the conserved C272/278 in P5 activity  
 
Some protein disulfide oxidoreductases (PDOs) with only a and a' domains have been 
reported to catalyze the refolding of scrambled RNase A [29-31]. In the present study, aa’ 
domain of P5 promoted the refolding of lysozyme (Fig. 13). However, P5 with a, a’, and b 
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domains inhibited the refolding by formation of hyLYS, in which catalytic cysteines in the a 
and a' domains of P5 participated comparably, and the conserved C272/278 in b domain 
played a key role to capture the substrate lysozyme. 
Jessop et al. have studied on substrates of PDI family, finding that P5 non-covalently 
interacts with immunoglobulin binding protein (BiP) [6]. The binding is redox-dependent, and 
P5 present with BiP, functions as a reductase in hyperoxidative conditions, suggesting that 
BiP may regulate P5 activity [6]. The hydrophobic cluster analysis using the drawhca 
program by Luc CANARD showed that P5 had hydrophobic-rich regions around C272/278 in 
b domain. Therefore, it is likely that the hydrophobic-rich regions of P5 could be associated 
with BiP to provide proper conformation to function as a reductase. The functional shift 
caused by C272/278A mutations (Fig. 28) suggests a possible allosteric regulation of P5 
activity, in which the conserved C272/278 are structurally necessary to decide whether P5 
functions as a significant sulfhydryl oxidase and a predominant reductase. 
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CONCLUSION 
 
Using domain and Cys-Ala variants, I demonstrated that P5 had potent sulfhydryl 
oxidase activity to catalyze formation of the trypsin-resistant lysozyme multimers with hyper 
molecular mass inactivated via intermolecular disulfide cross-linkages, in which the catalytic 
cysteines in both the a and a' domains of P5 participated comparably, and the conserved 
C272/278 in b domain played a key role to capture the substrate lysozyme. Furthermore, the 
C272/278A variant lost the potent sulfhydryl oxidase activity, however, showed predominant 
insulin reductase activity, implying the activity shift of P5 dependent on the circumstance 
around C272/278. These results provide new insight into the molecular basis of P5 function.  
  
 
TABLES 
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Table 1. Primers for P5 variants. 
 
 Forward Reverse 
a 5’-CGGGATCCCTCTATTCA
TCTAGTGACGATGTC-3’ 
5’-CCCAAGCTTCTAATCCTTCACGA
GCTGGCGCA-3’ 
aa’ 5’-CGGGATCCCTCTATTCA
TCTAGTGACGATGTC-3’ 
5-CCCAAGCTTTCAAAGAGCCCGG
GTAAC-3’  
a’b 5’-CGGGATCCGGTTCGGG
TAAGAAGGACGTG-3’ 
5’-CCCAAGCTTTCACAACTCATCCT
TCTCCAG-3’ 
b 5’-CGGGATCCACCCGGGC
TCTTGATCTG-3’ 
5’-CCCAAGCTTTCACAACTCATCCT
TCTCCAG-3’ 
C36A 5’-CTATGCTCCTTGGGCT
GGCCACTGAACCCG-3’ 
5’-CTTTGGCAGTGGCCAGCCCAAG
GAGCATAG-3’ 
C39A 5’-CTTGGTGTGGCCACGC
CCAAAGGTTGACAC-3’ 
5’-GTGTCAACCTTTGGGCGTGGCC
ACACCAAG-3’ 
C171A 5’-GCTCCTTGGGCTGGAC
ACTGCAAAAATC-3’ 
5’-GATTTTTGCAGTGTCCAGCCCA
AGGAGC-3’ 
C174A 5’-CTTGGTGTGGACACGC
CAAAAATCTAGAGC-3’ 
5’-GCTCTAGATTTTTGGCGTGTCCA
CACCAAG-3’ 
C36/39A 5’-CTTGGGCTGGCCACGC
CCAAAGGTTGACAC-3’ 
5’-GTGTCAACCTTTGGGCGTGGCC
AGCCCAAG-3’ 
C171/174A 5’-GGGCTGGACACGCCA
AAAATCTAGAGC-3’ 
5’-GCTCTAGATTTTTGGCGTGTCCA
GCCC-3’ 
C272/278A 5’-CACCAGCTCGCCGTAG
TGGCCGT-3’ 
5’-ACGGCCACTACGGCGAGCTGGT
G-3’ 
Primers used for domain-deleted or Cys-Ala mutants are listed. 
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Table 2. Conditions for purification of domain-deletion and Cys-Ala mutants.  
Alternative conditions for ammonium sulfate precipitation, hydrophobic, affinity (IMAC) and anion exchange chromatography are listed.  
 
Ammonium sulfate precipitation (%) (g/ 15 mL suspension) 
 Full-length a aa’ a’b b 
1
st
 80 (8.41) 42 (3.82) 37 (3.32) 37 (3.32)  
2
nd
 ― 60 (2.03) 70 (3.76) 60 (2.46)  
Hydrophobic chromatography: Basal buffer; 100 mM Tris-AcOH (pH 6.5) 
Basal loading buffer: 100 mM Tris-AcOH (pH 6.5)  Full-length*1 a aa’ a’b b 
Loading buffer  
including 
2M NaCl 2M NaCl 1M (NH4)2SO4 
Washing buffer  
including 
100 mM NaCl*
2 ― 
 
― 
Elution buffer  
including 
100 mM NaCl/ 
1% Triton-X100 
100 mM NaCl 
 
100 mM NaCl 
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Affinity chromatography (IMAC): Basal buffer; 50 mM sodium phosphate/ 150 mM NaCl (pH 7.8) 
Basal loading buffer: 100 mM NaCl/ 100 mM sodium phosphate (pH7.8)  Full-length*1 a aa’ a’b b 
Loading buffer 
100 mM sodium phosphate/  
300 mM NaCl*
3
 
  
 
 
Washing buffer  
including 
50 mM imidazole 
  
― 
 
Elution buffer  
including 
500 mM imidazole 
  50 mM 
imidazole 
 
Anion exchange chromatography: Basal buffer; 100mM Tris-HCl (pH7.0) 
Basal loading buffer: 100 mM Tris-HCl (pH 7.0)  Full-length a aa’ a’b b 
Loading buffer 100 mM Tris-HCl  
 
20 mM Tris-HCl  
  
Washing buffer  100 mM Tris-HCl  ― 20 mM Tris-HCl  ― 
Elution buffer  
including 
300 mM NaCl 150 mM NaCl 
 
150 mM NaCl 
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Shaded boxes: conditions for full-length P5, unshaded boxes: the same conditions as full length, dashes: non-operated. *
1
: Except for 
C272/278A. *
2
: C272/278A was eluted with washing buffer. *
3
: After loading of eluate including C272/278 A from hydrophobic 
chromatography, column was pre-washed with the loading buffer. 
 
  
 
FIGURES 
 
 
 
 
 
 
Fig. 1. Scheme of lysozyme refolding assay.  
 
To investigate isomerase activity of P5, the refolding of denatured lysozyme was monitored. Refolding was measured 
as the bacteriolytic effect against Micrococcus lysodeikticus cell wall suspension, with the accompanying decrease in 
absorbance at 540 nm. The denatured lysozyme was refolded for 60 min at 37℃ in refolding buffer containing 
GSSG/GSH in the presence or absence of P5 or its variants.  
-28- 
Fig. 2. Domain structures of PDI-P5 and its variants.  
 
(A) The domain structure of P5. The catalytic a and a' domains (open boxes) followed by the non-catalytic b domain 
(shaded box). The catalytic and non-catalytic cysteines are shown in bold and italic, respectively. Filled arrowheads 
indicate Cys positions with numbers. Shaded arrowheads show amino acid positions at domain boundaries. (B) 
Domain-deletion and Cys-Ala variants used are shown. Mutated catalytic and non-catalytic cysteines are represented 
in bold and italic bold, respectively. 
-29- 
B 
A 
Fig. 3. SDS-PAGE of the purified recombinant boar P5 and its mutants.  
 
Proteins were detected by silver staining. The motilities of molecular mass markers (rabbit muscle 
phosphorylase B, bovine serum albumin, hen egg white ovalbumin, bovine carbonic anhydrase, soy bean 
trypsin inhibitor, and hen egg white lysozyme) are indicated in kDa on the left side of the gel (a domain: 
12.5%, the other variants: 10% gel).  
-30- 
Fig. 4. Reductase activities of P5 and its variants.  
 
Reductive activities toward insulin in the presence of 1.0 mM DTT were examined by monitoring absorbance at 540 
nm. The assays were performed in duplicate in the presence or absence of P5 or its variants (0.19 µM). 
Representative data are shown in the graph. □, P5; ▲, a’b; ■, C36/39A; ●, C171/174A; ×, C36/39/171/174A; ○, 
DTT only.  
-31- 
Fig. 5. Dose-dependent effects of P5.  
 
Lysozyme activities in the presence of P5 at 0.7 and 0.15 µM are shown.  
□, lysozyme only; ▲, 0.15 µM; ●, 0.7 µM. hyLYS, lysozyme multimers with intermolecular 
disulfides and hyper molecular mass. 
-32- 
Fig. 6. Summary of lysozyme activities after 60min refolding in the presence or absence of P5 and its variants   
 
Lysozyme activities are shown in a table (A) and in a column chart (B). The refolding was monitored by the 
bacteriolytic effect of refolding lysozyme on Micrococcus lysodeikticus cell wall suspension. Reduced denatured 
lysozyme (1.4 μM final concentration) was added to refolding buffer containing glutathione redox agents (5 mM 
GSH/0.5 mM GSSG) and 0.7 µM recombinant P5 or its variants at 37℃, pH 7.0 (100 mM HEPES/5 mM MgCl2/20 
mM NaCl/2 mM EDTA). The assays were performed in triplicate in the presence or absence of P5 and its variants 
(0.7 µM) at 25℃. LYS, lysozyme. P5s, P5 or its mutants. Open boxes, catalytic domains without mutations. Shaded 
boxes, catalytic domains with Cys mutations. Dotted boxes, b domains.  
B 
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A 
Fig. 7. Effects of C36/39A and C171/174A on lysozyme refolding.  
 
Comparable effects of the double mutants at 0.7 µM □, lysozyme only; ●, C36/39A; ■, C171/174A; ○, P5. 
hyLYS; lysozyme multimers with intermolecular disulfides and hyper molecular mass. 
-34- 
Fig. 8.  Dose-dependent effects of C36/39A.  
 
Lysozyme activities in the presence of C36/39A at 0.7 and 0.15 µM are shown. 
□, lysozyme only; ▲, 0.15 µM; ●, 0.7 µM 
-35- 
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Fig. 9.  Dose-dependent effects of C171/174A.  
 
Lysozyme activities in the presence of C171/174A at 0.7 and 0.15 µM are shown. 
□, lysozyme only; ▲, 0.15 µM; ●, 0.7 µM 
Fig. 10. Effects of C36/39/171/174A and b domain on the refolding of lysozyme at 0.7 µM.  
 
C36/39/171/174A and b domain inhibited the refolding even without catalytic cysteines.  
□, lysozyme only; ▲, b; ×, C36/39/171/174A; ○, P5.  
-37- 
Fig. 11. Dose-dependent effects of C36/39/171/174A on lysozyme refolding.  
 
Lysozyme activities in the presence of C36/39 /171/174A  at 0.7 and 0.15 µM are shown. 
□, lysozyme only; ▲, 0.15 µM; ●, 0.7 µM. 
-38- 
-39- 
Fig. 12. Dose-dependent effects of b on lysozyme refolding.  
 
Lysozyme activities in the presence of b at 0.7 and 0.15 µM are shown.  
□, lysozyme only; ▲, 0.15 µM; ●, 0.7 µM. 
-40- 
Fig.13. Effects of the aa' domain on lysozyme refolding. 
 
(A) aa‘ accelerated lysozyme refolding at 0.3 µM. □, lysozyme only; ▲, aa’ (0.3 µM); ●, aa‘ domain (0.7 
µM) ; △, P5 (0.3 µM); ○, P5 (0.7 µM). In the presence of 0.7 µM of aa', the acceleration was decreased. 
Even in the presence of P5 at 0.3 µM, P5 inhibited lysozyme refolding (refolding activity; 10%, relative to 
lysozyme alone [17]). These results indicated that the aa' domain did not show inhibitory effect on the 
refolding. (B) Lysozyme product after 60 min refolding in the presence of aa’ domain. Lysozyme refolding 
product in the presence of aa’ at 0.7 µM was detected by anti-lysozyme antibody (α-LYS ) under the non-
reducing conditions (NR) as described in Fig. 18 to ensure aa’ did not form hyLYS at 0.7 µM; arrowhead, 
hyLYS, resulting in lysozyme refolding inhibition. 
A B 
Fig. 14. Effects of equimolar aa’and b on the refolding of lysozyme.  
 
Lysozyme refolding in the presence of aa’, b mixture was monitored.  
□, lysozyme only; ▲, aa' and b (0.7 µM); ■, b domain (0.7 µM). 
-41- 
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Fig. 15.  Dose-dependent effects of a’b.  
 
Lysozyme activities in the presence of a’b at 0.7 and 0.15 µM are shown. 
□, lysozyme only; ▲, 0.15 µM; ●, 0.7 µM 
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Fig. 16. Effects of equimolar a and a’b on the refolding of lysozyme.  
 
Lysozyme refolding in the presence of a, a’b mixture was monitored.  
□, lysozyme only; ▲, a and a' b (0.7 µM); ■, a' b domain (0.7 µM). 
Fig. 17. Western blotting analysis of the denatured lysozyme, P5, and its variants under the reducing 
conditions. 
 
 The denatured lysozyme, P5, and its variants were detected by anti-lysozyme antibody or anti-P5 antibody. α-
LYS, anti-lysozyme antibody; α-P5, anti-P5 antibody; R, under reducing conditions. *, nonspecific bands 
detected by α-P5 
-44- 
Fig. 18. Western blotting analysis of the products obtained by oxidative refolding of lysozyme.  
 
After refolding for 60min (Fig. 6), the refolding products were treated with an equal volume of 2% SDS sample 
buffer containing 5 mM NEM or 3 mM 2-Me at 100℃ for 3 min, and subjected to SDS-PAGE in a Tris-Tricine 
buffer system on a 7.5% gel. The membranes were probed with α-LYS. Refolding products of the denatured 
lysozyme alone, were sampled every 20 min for 1hr. QB, quenching buffer; RB, refolding buffer; LYS, lysozyme. 
NR, non-reducing conditions; R, reducing conditions; Lysozyme intermediates with intermolecular disulfide cross-
linkages are indicated by the square bracket.  
-45- 
Fig. 19. Lysozyme refolding products in the presence of P5 variants.  
 
Lysozyme refolding products after incubation for 60min in the presence of P5 variants at 0.7 µM were prepared in the 
same manner described in Figs. 6 and Fig. 18. The membranes were probed with α-LYS or α-P5. (A) In the presence or 
absence of P5 and its variants under the non-reducing conditions. (B) Under the reducing conditions. NR, non-reducing 
conditions; R, reducing conditions; *, non-specific bands; **, dimers of full-length P5 and b domain; ***, P5 and its 
variants at the hyper molecular region; arrowheads, lysozyme multimers at the hyper molecular region. Lysozyme 
intermediates with intermolecular disulfide cross-linkages are indicated by the square bracket.  
-46- 
A B 
Fig. 20. Comparison of lysozyme products in the presence of variants of catalytic domains.  
 
The refolding products twice as much as those of Fig. 19 in the presence or absence of P5 and the double mutant(s) or 
a’b were subjected to Western blotting and the amount of the lysozyme intermediates in the presence was compared. 
(A) In the presence of the double mutants. (B) In the presence of C36/39A and a’b. Arrowhead; hyLYS. Lysozyme 
intermediates were indicated by the square bracket. The lanes necessary were split from a single membrane and 
compared.  
-47- 
A B 
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Fig. 21. Refolding buffer did not cause migration of P5 and its variants to the hyper molecular region.  
 
P5 and its variants in the refolding buffer in the absence of denatured lysozyme were incubated for 60 min 
under the same conditions as Fig. 6 and subjected to Western blotting under the non-reducing conditions. *, 
non-specific bands; **, dimers.  
Fig. 22. Lysozyme multimers with hyper molecular mass independent of SDS concentration.  
 
Lysozyme refolding products after incubation for 60 min in the presence of C36/39/171/174A at 0.7 
µM were treated with 2% and 5% SDS sample buffer under the non-reducing and reducing conditions 
and detected by α-LYS or α-P5. The lanes necessary were split from a single membrane and compared. 
Arrowhead, lysozyme multimers with hyper molecular mass; *, C36/39/171/174A.  
-49- 
Fig. 23.  Migration of a’b and b domains to the hyper molecular mass in lysozyme refolding.  
 
Lysozyme refolding products in the presence of a’b and b at 0.7 µM were sampled every 20 min for 60 
min and detected by α-P5. *, non-specific bands; **, dimmers of b domain; arrowhead, b domain at the 
hyper molecular region. 
-50- 
Fig. 24. Formation rates of lysozyme multimers with hyper molecular mass in the presence of P5 and 
C36/39/171/174A.  
 
Lysozyme refolding products in the presence of P5 and C36/39/171/174A at 0.7 µM were sampled every 20 
min for 60 min and detected by α-LYS. Arrowhead, hyLYS formed by P5 and lysozyme multimers with 
hyper molecular mass formed by C36/39/171/174A. 
-51- 
Fig. 25. Comparison of trypsin sensitivities of native lysozyme, and reduced denatured lysozyme.  
 
Native lysozyme (nLYS), and reduced denatured lysozyme (dLYS) incubated for 60min in the presence or 
absence of trypsin were sampled every 30min, followed by treatment with 2% SDS sample buffer 
containing 5 mM NEM. Samples were subjected to SDS-PAGE as described in Fig. 18. RB, refolding 
buffer; Time, refolding and digestion time; Arrowhead, digested fragment of lysozyme.  
-52- 
-53- 
Fig. 26. Lysozyme multimers at the hyper molecular region formed by 
P5 more resistant to trypsin than those formed by C36/39/171/174A.  
 
Trypsin sensitivities of lysozyme multimers at the hyper molecular region 
formed by P5 and C36/39/171/174A at 0.7 µM were compared. Lysozyme 
products refolded for 60 min in the presence or absence of P5 and 
C36/39/171/174A, followed by trypsin treatment for 30 min were detected 
by α-LYS. R-time, refolding time; D-time, digestion time; arrowheads, 
hyLYS formed by P5 and lysozyme multimers with hyper molecular mass 
formed by C36/39/171/174A. Lanes 1-6 and lanes 7-12 were split from  a 
single membrane and compared, respectively. 
Fig. 27. Alignment of sequences around the conserved cysteines in b 
domain of P5 subfamily.  
 
A part of the sequences around the conserved cysteines in b domain of P5 subfamily are 
shown. Arrows, the conserved cysteines. The conserved non- catalytic cysteines at C272 
and C278 of boar mature P5, used in this study, are positioned at C291 and C297 in the 
precursor form. The listed 19 sequences are from BOAR (Sus scrofa, BAJ11758), 
BOVINE (Bos taurus, NP_001193274), MOUSE (Mus musculus, NP_082235), RAT 
(Rattus norvegicus, PDIA6_RAT), HUMAN (Homo sapiens, AAH01312), CHICKEN 
(Gallus gallus, XP_419952), XENOPUS (Xenopus tropicalis, CAJ82905), DANIO 
(Danio rerio, NP_922915), LANCELET (Branchiostoma floridae, EEN42176), 
NEMATOSTELLA (Nematostella vectensis, XP_001629218), CAENORHABDITIS 
(Caenorhabditis elegans, PDIA6_CAEEL), DROSOPHILA (Drosophila melanogaster, 
NP_609792), CIONA (Cionaintestinalis, XP_009857523), ORIZA (Oryza sativa 
Japonica Group, PDI23_ORYSJ), ZEA (Zea mays, NP_001105804), TRITICUM 
(Triticum aestivum, CBG91909), GLYCINE (Glycine max, NP_001236576), 
ARABIDOPSIS (Arabidopsis thaliana, AEC08762) and PHYSCOMITRELLA 
(Physcomitrella patens, EDQ54468). The sequences were aligned using the CLUSTALW 
program. 
 
P5_BOAR                SEDVAKKSCEEHQLCVVAVLPHILDTGAAGRNSYLEVLLKLADKYKKKMWGWLWTEAGAQ 342 
P5_BOVINE              NEDVAKKTCEEHQLCVVAVLPHILDTGAAGRNSYLEVLLKLADKYKKKMWGWLWTEAGAQ 342 
P5_MOUSE               NEDIAKKTCEEHQLCVVAVLPHILDTGAAGRNSYLEVLLKLADKYKKKMWGWLWTEAGAQ 347 
P5_RAT                 NEDIAKKTCEEHQLCVVAVLPHILDTGATGRNSYLEVLLKLADKYKKKMWGWLWTEAGAQ 342 
P5_HUMAN               NEDIAKRTCEEHQLCVVAVLPHILDTGAAGRNSYLEVLLKLADKYKKKMWGWLWTEAGAQ 342 
P5_CHICKEN             NEDVLKTTCDAHQLCIISVLPHILDTGASGRNSYLDVMLKMAEKYKKKMWGWLWTEAGAQ 348 
P5_XENOPUS             NGDIVKKTCDEHQLCIVAVLPHILDTGASGRNSYLDVMMKMADKYKKKMWGWLWAEAGAQ 343 
P5_DANIO               NEGILKKTCEDYQLCIIAVLPHILDTGASGRNSYLEVMKTMAEKYKKKMWGWLWTEAGAQ 342 
P5_LANCELET            GSEVMKA-CAEKQLCVVSFLPHILDTGASGRNQYLEQLRMMGEKYKKKVWGWVWAEAGAQ 342 
P5_NEMATOSTELLA        SNEVLKEGCNEHPICVIAFLPHILDSGASGRNTYLANLKELGEKYKKNRWGWLWSEAAAQ 330 
P5_CAENORHABDITIS      NQQVVEDACKEKQLCIFAFLPHILDCQSECRNNYLAMLKEQSEKFKKNLWGWIWVEGAAQ 345 
P5_DROSOPHILA          NESTFETACEGKPLCVVSVLPHILDCDAKCRNKFLDTLRTLGEKFKQKQWGWAWAEGGQQ 338 
P5_CIONA               SQEVFDENCGTH-LCILAFLPDIADDGKDGRNRYIDLLKSLGDRFKKQRWGWAWLPANAN 341 
P5_ORIZA               GPDAMEEKCASAAICFVSFLPDILDSKAEGRNKYLELLLSVAEKFKKSPYSFVWTAAGKQ 344 
P5_ZEA                 GPDVMEEKCASAAICFVSFLPDILDSKAEGRNKYLELLLSVAEKFKKSPYSFVWTAAGKQ 342 
P5_TRITICUM            SADVMEEKCASAAICFVSFLPDILDSKAEGRNKYLELLLSVAEKFKKSPYSFVWAGAGKQ 343 
P5_GLYCINE             SPDVLEEKCGSAAICFVAFLPDILDSKAEGRNRYLQQLLSVAEKFKRSPYSYVWVAAGKQ 341 
P5_ARABIDOPSIS         GPDVMEKKCGSAAICFISFLPDILDSKAEGRNKYLEMLLSVAEKFKKQPYSFMWVAAVTQ 341 
P5_PHYSCOMITRELLA      GQDVLDKECGSAAICFVSFLPDILDSKAEGRNKYLATLRNVAEKYKRN--------AYRQ 336 
-54- 
Fig. 28. Effect of C272/278A on lysozyme refolding 
 
(A) Lysozyme activity in the presence of C272/278A were examined to find moderate 
inhibition of lysozyme activity in the presence of  C272/278A 
□, lysozyme only; ■, C272/278A; ○, P5; ×, C36/39/171/174A. 
-55- 
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Fig. 28. Effect of C272/278A on lysozyme refolding 
 
(B) Western blotting analysis of lysozyme refolding products in the 
presence of C272/278A, P5 and C36/39/171/174A at 0.7 µM. Refolding 
products in the presence of C272/278A were sampled every 20 min. *, 
P5, C36/39/171/174A and C272/278A in monomeric forms; **, P5 and 
C36/39/171/174A at the hyper molecular region. Arrowheads, hyLYS 
formed by P5 and lysozyme multimers with hyper molecular mass 
formed by C36/39/171/174A. 
B 
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Fig. 28. Predominant reductase activity of C272/278A.  
 
(C) Comparison of insulin reductase activities in the in the presence of C272/278A, P5 and 
C36/39/171/174A at 0.19 µM.  
○, P5; ■, C272/278A; ×, C36/39/171/174A; □, DTT only. 
C 
  
 
APPENDICES 
 
 
 
 
 
 
 
 
App. 1. PDI catalyzes the formation, isomerization, and reduction 
of disulfide bonds of proteins. 
 
PDI plays the centering role for protein folding. Picture from Multiple 
ways to make disulfides, N. Bulleid and L. Ellgaard, Cell Press 36 
(2011)  485-492. 
 
-58- 
App. 2. Domain structures of PDI family members. 
 
Domain structures of some PDI family are shown. PDI family is characterized 
with one or more  thioredoxin domain(s). Catalytic domains include typically 
CXXC active site(s), involved in the formation, isomerization, and reduction 
of disulfide bonds. Some catalytic motives include Ser as shown in ERp44. 
pfPDO, protein disulfide oxidoreductase from Pyrococcus furiosus. 
 
-59- 
App. 3. A cooperative quality control network in the redox pathway. 
 
A hierarchical electron transfer network centering on the PDI-Ero1α 
complex, including ERp57, ERp46, and P5 [7]. 
-60- 
App. 4. Tumor immune evasion triggered by disulfide reduction. 
 
While tumors in early stage undergo carcinolysis, those in advanced 
stage form transient mixed disulfide complexes via MICA, followed by 
the disulfides reduction, causing its conformational change. The change 
enables proteolytic cleavage of MICA from membrane surface, resulting 
in tumor progression. MICA, major histocompatibility complex class I-
related ligand [13]. 
-61- 
App. 5. Sorting promotion of GFP-AB by PDIL2;3. 
 
Sorting promotion of GFP-AB, the N-terminal region of α-globulin fused 
to GFP, by PDIL2;3 (a rice orthologue of human P5) is illustrated. (A) 
PDIL2;3 retains GFP-AB within the ER by accumulating it via 
intermolecular disulfide cross-linkages, and promote sorting of the 
protein to protein body Ⅰ (PB-Ⅰ). (B) The knockdown of PDIL2;3 
inhibits the efficient localization of GFP-AB in PB-Ⅰ and promotes its 
exit from the ER. [16] 
A 
B 
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App. 6. P5 inhibits oxidative refolding of denatured lysozyme to form 
lysozyme multimers with intermolecular disulfides and hyper molecular 
mass. 
 
(A) Effects of ERp57 and P5 on oxidative refolding. (B) Western blotting of 
the refolding products after incubation for 60 min in the presence of ERp57 
and P5. P5 forms hyLYS in dose dependent manner. Box, hyLYS.  
Note that lysozyme in multimeric forms (lane 2) refolded and detected as a 
monomer in the presence of ERp57 (lanes 5 and 6), while those migrated to 
the hyper molecular region and detected as the hyLYS in the presence of P5 
(lanes 3 and 4). Conc., concentration (µM) [17]. 
A 
B 
1 2 3 4 5 6 
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App. 7. The hydrophobic-rich regions around C272/278 in b domain. 
 
The hydrophobic regions predicted by Luc CANARD are colored in green. 
Asterisks, the positions of cysteines. Even with cysteine mutations, the 
hydrophobic region same as P5 are shown. 
-64- 
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